Plantacor

Plantacor is a preclinical-stage biotech leveraging natural product chemistry to develop novel oncology therapeutics. The company has established a proprietary formulation platform to enhance the delivery and reduce the toxicity of difficult-to-solubilize small molecules. Its lead program, CDIM 9, is in late-stage preclinical development for basal-like breast cancer, an aggressive subtype with limited treatment options. Plantacor operates from College Station, Texas, benefiting from proximity to major research institutions and has utilized over $9M in grant-funded research to build its pipeline.

Proprietary formulation platform for enhancing solubility, bioavailability, and reducing toxicity of difficult-to-formulate small molecule compounds derived from natural products. Supports oral, intraperitoneal, and other parenteral delivery.

Plantacor competes in the crowded oncology space, specifically in TNBC, against large pharma, biotech companies, and novel modalities like antibody-drug conjugates and immunotherapies. Its differentiation lies in its natural product-derived analogs and its proprietary delivery platform aimed at improving efficacy and safety profiles.